Insulin therapy is indicated if glycemic control is not achieved with medications and/or non-insulin injectables, or if symptomatic hyperglycemia or a catabolic picture is present. Initiating basal insulin analogs, such as glargine and detemir, is the regimen of choice. Ultra-long-acting analogs, such as glargine U300 and degludec, have shown greater consistency and reduced glycemic variability, making them suitable for the elderly or individuals at increased risk of nocturnal hypoglycemia. However, traditional basal insulin analogs require at least one daily injection, which can be cumbersome and often leads to poor adherence, ultimately challenging many patients with type 2 diabetes mellitus (T2DM).